FERI Group and Target Global Join Forces for New Growth Fund
24.11.2020 11:00:00 EET | Business Wire | Press release
The Bad Homburg-based FERI Group is cooperating with Target Global in the management and placement of a new growth fund. The two companies will work together in the selection of target investments and the placement of this new alternative investment fund for growth capital. This cooperation between one of the leading investment houses in the German-speaking region and one of the most active European venture capital investment companies is the first of its kind.
The new Target Global Growth Fund offers investment opportunities in selected growth companies to semi-professional and professional investors. The fund will invest in start-ups with strong growth potential that offer digital products and services in typical European industries for large and preferably global markets – mainly market platforms, Fintechs and service software providers. The fund's investment focus is on companies in early and mid growth phases with valuations in excess of EUR 50 million.
"The fund opens up new investment opportunities in the highly attractive sector of strong growing technology companies," says Marcel Renné, CEO of FERI AG. "We are very pleased about the partnership with Target Global. By combining our investment know-how with the high level of expertise of Target Global, we will be able to jointly develop the venture growth market."
"The European tech ecosystem shows impressive growth, European start-ups increasingly establish themselves as global industry leaders, but there is still a lack of European capital, especially in the growth phases," says Yaron Valler, Managing General Partner at Target Global. "We are proud of having won a renowned partner like FERI for jointly advancing European tech success stories."
The Target Global team has invested in digital technologies and start-up companies throughout Europe and Israel for more than 15 years. The company follows three active investment strategies - early stage, growth stage and a dedicated mobility fund. The second early stage fund, Early Stage Fund II, was launched in January 2020. The new growth fund will increase the assets managed/advised by Target Global to over €1 billion. Its portfolio includes companies such as Auto1, Delivery Hero, Rapyd, Travelperk and WeFox.
About Target Global
Target Global is an international venture capital investor headquartered in Berlin, Germany, with approximately 800 million Euros in assets under management. Target Global has additional offices in London, Tel Aviv and Barcelona, linking the major European start-up ecosystems and building on a strong global network. With an experienced team of investment and operational experts, the goal is to help exceptional entrepreneurs become market leaders. Through its funds, Target Global aims to invest in fast-growing tech start-ups in markets worth billions. The Target Global partners have been investing in digital technologies for more than 15 years in some cases and are investors behind major European start-up success stories.
More about Target Global: https://www.targetglobal.vc/
About FERI Group
Founded in 1987 and headquartered in Bad Homburg, Germany, the FERI Group has developed into one of the leading investment houses in the German-speaking area. FERI offers tailor-made solutions for institutional investors, family assets and trusts in the following areas:
- Investment Management: institutional asset management and private wealth management
- Investment Consulting: advisory services for institutional investors and family offices
- Investment Research: macroeconomic forecasts and asset allocation analyses
The FERI Cognitive Finance Institute was formed in 2016. It is the strategic research centre and creative think tank of the FERI Group. The Institute focuses on innovative analyses and the development of methods for long-term oriented economic and capital market research.
FERI and MLP currently have assets of EUR 39.2 billion under management. A total of EUR 8.5 billion of these assets are alternative investments. The FERI Group is headquartered in Bad Homburg and has offices in Dusseldorf, Hamburg, Luxembourg, Munich, Vienna and Zurich.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005428/en/
Contact information
Press contacts Target Global:
Instinctif Partners
Ross Gillam, Nick Corrin
020 7457 2020
ross.gillam@instinctif.com
nick.corrin@instinctif.com
Press contact FERI:
FERI AG
Katja Liese
Tel.: +49 (0)6172 / 916-3192
presse@feri.de
www.feri.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom